Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expr...
Publications
2 shownOsimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
In patients with stage IB to IIIA <i>EGFR</i> mutation-positive NSCLC, disease-free survival was significantly longer among those who received osimertinib than among those who r...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 4,305
- Institution
- Asan Medical Center
External Links
Identifiers
- ORCID
- 0000-0003-1065-8095
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.